Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non–Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

J. Nicholas Bodor, Jyoti D. Patel, Heather A. Wakelee, Benjamin Levy, Hossein Borghaei, Bruna Pellini, Michael R. Costello, Jonathan E. Dowell, Gene Grant Finley, Chao Huang, Joel W. Neal, Jorge J. Nieva, Sonam Puri, Mark A. Socinski, Christian A. Thomas, Eric A. Ross, Samuel Litwin, Margie L. Clapper, Joseph TreatClinical 2023 · DOI

BibTeX
@inproceedings{bodor2023phase,
  author = {J. Nicholas Bodor and Jyoti D. Patel and Heather A. Wakelee and Benjamin Levy and Hossein Borghaei and Bruna Pellini and Michael R. Costello and Jonathan E. Dowell and Gene Grant Finley and Chao Huang and Joel W. Neal and Jorge J. Nieva and Sonam Puri and Mark A. Socinski and Christian A. Thomas and Eric A. Ross and Samuel Litwin and Margie L. Clapper and Joseph Treat},
  title = {{Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non–Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked}},
  booktitle = {Clinical},
  year = {2023},
  doi = {10.1016/j.cllc.2023.05.003},
}

Loading related content...

Figure